# 2025年10月25日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 解锁乳酸在危重症患者中的代谢与抗炎治疗潜力

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41137071](https://pubmed.ncbi.nlm.nih.gov/41137071)
**期刊：** Critical care (London, England)
**PMID：** 41137071
**DOI：** 10.1186/s13054-025-05665-4

### 第一部分 原文与翻译

**英文原标题：** Unlocking the metabolic and anti-inflammatory therapeutic potential of lactate in critically ill patients.

**英文摘要原文：**
BACKGROUND: Lactate, traditionally viewed as a biomarker of hypoxia and severity in critical illness, has recently emerged as a potential therapeutic agent. Its roles extend beyond energy metabolism to include anti-inflammatory and signaling functions. This review explores the evolving evidence supporting lactates therapeutic application in critical care settings.

MAIN BODY: We synthesize current knowledge on lactate physiology, including its production, transport, and metabolism across organs. Experimental models and clinical studies data suggest that exogenous lactate, particularly in the form of hypertonic sodium lactate (HSL), improves hemodynamics, reduces inflammation, and enhances organ function in sepsis, acute heart failure, and brain injury. Lactate administration shows promise in restoring metabolic homeostasis, improving microcirculation, and supporting cardiac and cerebral recovery. However, clinical studies in critical care remain limited, largely because lactate is predominantly regarded as a marker of poor prognosis rather than as a potential energy substrate with therapeutic value.

CONCLUSION: Lactate-based therapy represents a paradigm shift in the management of critical illness. While preclinical data are promising, larger, well-designed randomized trials are needed to establish its safety, efficacy, and optimal indications. The therapeutic repositioning of lactate could complement or replace current resuscitation fluids and metabolic modulators in intensive care unit (ICU).

**中文摘要译文：**
背景：乳酸，传统上被视为缺氧和危重症严重程度的生物标志物，最近已成为一种潜在的治疗药物。其作用不仅限于能量代谢，还包括抗炎和信号传导功能。本综述探讨了支持乳酸在重症监护环境中治疗应用的最新证据。

主体：我们综合了当前关于乳酸生理学的知识，包括其在各器官中的产生、转运和代谢。实验模型和临床研究数据表明，外源性乳酸，特别是以高渗乳酸钠（HSL）形式，在脓毒症、急性心力衰竭和脑损伤中可改善血流动力学、减少炎症并增强器官功能。乳酸给药在恢复代谢稳态、改善微循环以及支持心脏和大脑恢复方面显示出潜力。然而，重症监护领域的临床研究仍然有限，主要是因为乳酸主要被视为预后不良的标志物，而不是具有治疗价值的潜在能量底物。

结论：基于乳酸的治疗代表了危重症管理的一个范式转变。虽然临床前数据很有希望，但仍需要更大规模、精心设计的随机试验来确定其安全性、有效性和最佳适应症。乳酸的重新定位治疗可能补充或替代重症监护病房（ICU）中当前的复苏液体和代谢调节剂。

### 第二部分 AI 大师评价

本研究通过系统综述方法，深入探讨了乳酸从传统生物标志物向治疗药物的角色转变。该研究整合了乳酸生理学基础知识和最新临床证据，发现外源性乳酸（特别是高渗乳酸钠）在脓毒症、急性心衰和脑损伤等危重症中具有改善血流动力学、抗炎和器官保护的多重作用。这项研究的创新性在于颠覆了传统认知，将乳酸重新定位为具有治疗价值的能量底物和信号分子，代表了危重症治疗的重要范式转变。虽然临床前证据充分，但该领域仍需大规模随机对照试验验证其临床应用价值，这一发现有望为ICU治疗策略带来革命性变革。

---

## 2. 抑制PGK1通过失活PKM2/ALOX12/铁死亡通路改善急性肾损伤：一项雄性小鼠研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136411](https://pubmed.ncbi.nlm.nih.gov/41136411)
**期刊：** Nature communications
**PMID：** 41136411
**DOI：** 10.1038/s41467-025-64480-1

### 第一部分 原文与翻译

**英文原标题：** Inhibition of PGK1 ameliorates acute kidney injury through inactivating the PKM2/ALOX12/ferroptosis pathway in a study with male mice.

**英文摘要原文：**
Despite decades of studies into the mechanisms underlying acute kidney injury (AKI), the effective clinical therapies are still limited. Here we report that the development of AKI was attenuated by conditional knockout of phosphoglycerate kinase 1 (PGK1) in renal tubular epithelial cells (RTECs) and aggravated by specific overexpression of PGK1 and administration of 3-phosphoglycerate (3-PG) in male mice. PGK1 interacted with pyruvate kinase M2 (PKM2), inducing PKM2 phosphorylation, promoting the formation of the PKM2 dimer and the subsequent nuclear translocation of PKM2. In the nucleus, the interaction of PKM2 with Pknox1 potentiated the enrichment of Pknox1 within ALOX12 promoters, which resulted in ALOX12-mediated ferroptosis in RTECs. Our drug screening experiments identified L7DG as a potential PGK1 inhibitor which exhibited protective effects against ischemic/reperfusion (I/R)-induced renal injury. Overall, we establish that genetic and pharmacological inhibition of PGK1 might be proposed as an avenue for managing AKI.

**中文摘要译文：**
尽管对急性肾损伤（AKI）潜在机制的研究已有数十年，但有效的临床治疗方法仍然有限。本文报道，在雄性小鼠中，通过条件性敲除肾小管上皮细胞（RTECs）中的磷酸甘油酸激酶1（PGK1）可减轻AKI的发展，而特异性过表达PGK1和施用3-磷酸甘油酸（3-PG）则会加重AKI。PGK1与丙酮酸激酶M2（PKM2）相互作用，诱导PKM2磷酸化，促进PKM2二聚体的形成以及随后的PKM2核转位。在细胞核中，PKM2与Pknox1的相互作用增强了Pknox1在ALOX12启动子区域的富集，从而导致ALOX12介导的RTECs铁死亡。我们的药物筛选实验鉴定出L7DG作为一种潜在的PGK1抑制剂，对缺血/再灌注（I/R）诱导的肾损伤表现出保护作用。总之，我们证实遗传和药理学抑制PGK1可能被提出作为管理AKI的一种途径。

### 第二部分 AI 大师评价

本研究旨在探索急性肾损伤（AKI）的新治疗靶点，通过基因操作和药物筛选方法，系统揭示了PGK1-PKM2-ALOX12信号轴在AKI发生发展中的关键作用。研究发现PGK1通过调控PKM2的磷酸化、二聚化和核转位，进而激活ALOX12介导的铁死亡通路，最终导致肾小管上皮细胞损伤。该研究的创新性在于首次阐明了PGK1在AKI中的分子机制，并成功筛选出具有治疗潜力的PGK1抑制剂L7DG。这项工作不仅为AKI的发病机制提供了新的理论见解，更重要的是为开发靶向PGK1的AKI治疗药物奠定了重要基础，具有显著的临床转化价值。需要注意的是，目前研究仅限于雄性小鼠模型，未来需要在更多物种和性别中进行验证。

---

## 3. 致编辑的信："危重症患者中非甾体抗炎药肾毒性发生率"

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41135129](https://pubmed.ncbi.nlm.nih.gov/41135129)
**期刊：** Journal of critical care
**PMID：** 41135129
**DOI：** 10.1016/j.jcrc.2025.155319

### 第一部分 原文与翻译

**英文原标题：** Letter to the editor: "Incidence of kidney toxicity of non-steroidal anti-inflammatory drugs in critically ill patients".

**英文摘要原文：**
This commentary provides a critical appraisal of the recent retrospective cohort study conducted by Gomes et al., which investigated the association between non-steroidal anti-inflammatory drug (NSAID) administration and acute kidney injury (AKI) in critically ill patients. While the study offers notable contributions, particularly its extensive nine-year data collection period and the identification of an elevated risk of severe AKI (KDIGO stage 3) associated with NSAID use, several methodological limitations merit attention. These include insufficient characterization of NSAID exposure parameters (e.g., dosage, timing, and cumulative exposure), potential confounding by indication as evidenced by higher AKI rates in younger, less critically ill patients receiving NSAIDs, and limited generalizability due to the exclusion of individuals with pre-existing renal impairment. To address these limitations, we recommend that future studies adopt standardized NSAID administration protocols, employ advanced analytical methods such as propensity score matching to mitigate treatment selection bias, and investigate alternative analgesic strategies for high-risk populations. Furthermore, the development of evidence-based clinical practice guidelines and cost-effectiveness analyses is essential to inform healthcare policy. Despite these concerns, the study provides valuable insights into the association between NSAID use and severe AKI, as well as long-term mortality outcomes, highlighting the necessity for cautious NSAID utilization and enhanced renal monitoring in critically ill patients. Multicenter prospective studies with comprehensive exposure assessment and mechanistic investigations are imperative to deepen clinical understanding and improve outcomes in this vulnerable population.

**中文摘要译文：**
本评论对Gomes等人最近开展的回顾性队列研究进行了批判性评价，该研究调查了危重症患者中非甾体抗炎药（NSAID）给药与急性肾损伤（AKI）之间的关联。虽然该研究做出了显著贡献，特别是其长达九年的广泛数据收集期以及识别出与NSAID使用相关的严重AKI（KDIGO第3期）风险升高，但若干方法学局限性值得关注。这些包括NSAID暴露参数（如剂量、时间和累积暴露）的表征不足，潜在的适应症混杂（表现为接受NSAID治疗的较年轻、病情较轻患者中AKI发生率较高），以及由于排除了已有肾功能损害个体而导致的有限普适性。为解决这些局限性，我们建议未来研究采用标准化的NSAID给药方案，使用倾向评分匹配等先进分析方法来减轻治疗选择偏倚，并针对高危人群研究替代性镇痛策略。此外，制定基于证据的临床实践指南和成本效益分析对于指导医疗政策至关重要。尽管存在这些担忧，该研究为NSAID使用与严重AKI以及长期死亡率结果之间的关联提供了有价值的见解，强调了在危重症患者中谨慎使用NSAID和加强肾功能监测的必要性。开展多中心前瞻性研究，结合全面的暴露评估和机制研究，对于深化临床理解并改善这一脆弱人群的预后至关重要。

### 第二部分 AI 大师评价

本研究是对Gomes等人关于危重症患者NSAID使用与急性肾损伤关联的回顾性队列研究的批判性评述。该研究通过长达九年的数据收集，识别出NSAID使用与严重AKI（KDIGO第3期）风险升高的显著关联，并探讨了长期死亡率结局。其创新性在于对危重症这一特殊人群NSAID安全性的系统性评估，但受限于回顾性设计，存在暴露参数表征不足、适应症混杂等局限性。该研究具有重要的临床价值，为危重症患者镇痛药物选择提供了循证依据，强调了NSAID使用的风险意识和肾功能监测的必要性，对改善危重症患者管理具有重要指导意义。

---

## 4. 小气道黏液栓与重塑：哮喘复杂气道行为与不稳定性考量

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41135034](https://pubmed.ncbi.nlm.nih.gov/41135034)
**期刊：** American journal of respiratory and critical care medicine
**PMID：** 41135034
**DOI：** 10.1164/rccm.202508-1859ED

### 第一部分 原文与翻译

**英文原标题：** Mucus Plugs and Remodeling in the Small Airways: Considerations for Complex Airway Behavior and Instability in Asthma.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究聚焦于哮喘中小气道黏液栓形成与气道重塑的病理生理机制，探讨其对复杂气道行为和不稳定性的影响。该研究通过分析小气道结构变化与功能紊乱的关系，揭示了黏液栓在哮喘气道不稳定性中的关键作用。这一视角具有重要的创新性，为理解哮喘异质性和难治性提供了新的病理生理学基础，对开发针对小气道病变的靶向治疗策略具有重要临床价值。然而，由于缺乏详细的研究方法和具体数据，其临床应用和验证仍需进一步研究证实。

---

## 5. 脂筏蛋白质组学鉴定内皮肌球蛋白-9（MYH9）为低密度脂蛋白跨细胞转运和动脉粥样硬化的调节因子

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41134623](https://pubmed.ncbi.nlm.nih.gov/41134623)
**期刊：** Proceedings of the National Academy of Sciences of the United States of America
**PMID：** 41134623
**DOI：** 10.1073/pnas.2509315122

### 第一部分 原文与翻译

**英文原标题：** Lipid raft proteomics identify endothelial myosin-9 (MYH9) as a regulator of low-density lipoprotein transcytosis and atherosclerosis.

**英文摘要原文：**
BACKGROUND: In early atherosclerosis, circulating Low-Density Lipoprotein (LDL) crosses the endothelium by transcytosis. This involves caveolar uptake of LDL by scavenger receptor BI (SR-BI) and activin-like kinase 1 (ALK1) and requires the protein caveolin-1 (Cav-1). We identified mediators of LDL transcytosis by isolating membrane microdomains enriched in caveolin-1 from human coronary endothelial cells (HCAECs) treated with LDL and performing mass spectrometry. One of the proteins identified was myosin-9 (MYH9).

METHODS: Total internal reflection fluorescence microscopy was conducted to measure LDL transcytosis by HCAECs. We measured LDL transcytosis in vivo in mice lacking endothelial MYH9 (EC-). Atherosclerosis studies were also performed in EC- deleted of hepatic LDLR via (adeno-associated virus, AAV)-CRISPR. Additionally, we performed analysis of human transcriptomic data.

RESULTS: Gene ontology analysis in human aortic endothelial cells suggested a role for MYH9 in exocytosis. Both knockdown and pharmacologic inhibition of MYH9 inhibited LDL transcytosis. MYH9 depletion caused an accumulation of LDL-containing vesicles at the base of the cell; overexpression caused an increase in LDL exocytosis. EC- mice accumulated less LDL in the aortic arch after acute injection with LDL. To investigate the role of MYH9 in atherosclerosis, we deleted hepatic LDL in EC- mice using AAV-CRISPR and fed them a high-fat diet. The aortic arch and root of AAV-CRISPR; EC- mice exhibited smaller plaques. Human transcriptomic data showed greater messenger RNA (mRNA) levels of aortic  in atherosclerotic aortas compared to healthy controls.

CONCLUSIONS: Lipid raft proteomics identified MYH9 as a regulator of LDL transcytosis. MYH9 is required for endothelial LDL exocytosis and contributes to early atherosclerosis.

**中文摘要译文：**
背景：在早期动脉粥样硬化中，循环低密度脂蛋白（LDL）通过跨细胞转运穿过内皮。这一过程涉及通过清道夫受体BI（SR-BI）和激活素样激酶1（ALK1）对小窝摄取LDL，并需要蛋白小窝蛋白-1（Cav-1）的参与。我们通过从经LDL处理的人冠状动脉内皮细胞（HCAECs）中分离富含小窝蛋白-1的膜微区并进行质谱分析，鉴定了LDL跨细胞转运的介质。鉴定出的蛋白之一是肌球蛋白-9（MYH9）。

方法：采用全内反射荧光显微镜测量HCAECs的LDL跨细胞转运。我们在缺乏内皮MYH9（EC-）的小鼠体内测量了LDL跨细胞转运。还通过（腺相关病毒，AAV）-CRISPR在EC-小鼠中删除肝LDLR进行了动脉粥样硬化研究。此外，我们分析了人类转录组数据。

结果：人主动脉内皮细胞的基因本体分析提示MYH9在外泌作用中发挥作用。MYH9的敲低和药理学抑制均抑制了LDL跨细胞转运。MYH9耗竭导致含LDL的囊泡在细胞底部积聚；过表达导致LDL外泌增加。EC-小鼠在急性注射LDL后主动脉弓中积累的LDL较少。为了研究MYH9在动脉粥样硬化中的作用，我们使用AAV-CRISPR删除了EC-小鼠的肝LDL，并给予高脂饮食。AAV-CRISPR；EC-小鼠的主动脉弓和根部表现出较小的斑块。人类转录组数据显示，与健康对照组相比，动脉粥样硬化主动脉中的主动脉信使RNA（mRNA）水平更高。

结论：脂筏蛋白质组学鉴定MYH9为LDL跨细胞转运的调节因子。MYH9是内皮LDL外泌所必需的，并有助于早期动脉粥样硬化。

### 第二部分 AI 大师评价

本研究通过脂筏蛋白质组学方法系统性地揭示了肌球蛋白-9（MYH9）在低密度脂蛋白跨细胞转运和动脉粥样硬化发生中的关键作用。研究采用多层次验证策略，包括细胞水平的功能验证、动物模型实验和人类转录组数据分析，方法学严谨。核心发现是MYH9通过调控LDL的外泌过程参与早期动脉粥样硬化形成，这一机制为理解动脉粥样硬化的发病机制提供了新的分子基础。研究的创新性在于首次将MYH9与LDL跨内皮转运联系起来，为开发针对早期动脉粥样硬化的新型治疗靶点提供了理论依据。然而，研究主要聚焦于早期病变阶段，对MYH9在晚期动脉粥样硬化中的作用仍需进一步探索。

---

## 6. 闭环胰岛素输注在妊娠期1型糖尿病中的应用：CIRCUIT随机临床试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41134589](https://pubmed.ncbi.nlm.nih.gov/41134589)
**期刊：** JAMA
**PMID：** 41134589
**DOI：** 10.1001/jama.2025.19578

### 第一部分 原文与翻译

**英文原标题：** Closed-Loop Insulin Delivery in Type 1 Diabetes in Pregnancy: The CIRCUIT Randomized Clinical Trial.

**英文摘要原文：**
IMPORTANCE: Hyperglycemia-related pregnancy complications occur in 50% of pregnant women with type 1 diabetes. Closed-loop insulin systems improve glycemia outside of pregnancy but have had limited testing in pregnancy.

OBJECTIVE: To assess the efficacy of a closed-loop system in pregnancy.

DESIGN, SETTING, AND PARTICIPANTS: Open-label trial enrolling pregnant women with type 1 diabetes at 14 clinical centers in Canada and Australia before 14 weeks' gestation with follow-up until 6 weeks postpartum. Enrollment occurred between June 2021 and July 2024 and follow-up was completed in March 2025.

INTERVENTIONS: Participants were randomized 1:1 to closed-loop therapy (n = 46) or standard care (insulin pump or multiple daily insulin injections) (n = 45) with continuous glucose monitoring.

MAIN OUTCOMES AND MEASURES: The primary outcome was the percentage of time spent in the pregnancy-specific glucose range (63-140 mg/dL), measured by continuous glucose monitoring from 16 to 34 weeks' gestation.

RESULTS: Among 94 enrolled participants, 3 experienced pregnancy loss prior to randomization, 91 were randomized (mean age, 31.7 [SD, 5.2] years; early pregnancy hemoglobin A1c, 7.4% [SD, 1.0%]), and 88 were included in the primary analysis. The mean percentage of time spent in the pregnancy-specific glucose range from 16 to 34 weeks' gestation was 65.4% in the closed-loop group and 50.3% in the standard care group (mean adjusted difference, 12.5 [95% CI, 9.5-15.6] percentage points; P < .001). There was 1 episode of severe hypoglycemia in the closed-loop group, and there were 2 episodes of diabetic ketoacidosis in the closed-loop group and 1 in the standard care group.

CONCLUSION AND RELEVANCE: Pregnant women with type 1 diabetes using a closed-loop system spent significantly more time in the pregnancy-specific glucose range than those receiving standard care. These findings support the use of this closed-loop system in pregnant women with type 1 diabetes.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04902378.

**中文摘要译文：**
重要性：50%的1型糖尿病孕妇会发生高血糖相关妊娠并发症。闭环胰岛素系统在非妊娠期可改善血糖控制，但在妊娠期的测试有限。

目的：评估闭环系统在妊娠期的疗效。

设计、设置和参与者：在加拿大和澳大利亚的14个临床中心开展的开放标签试验，招募妊娠14周前的1型糖尿病孕妇，随访至产后6周。入组时间为2021年6月至2024年7月，随访于2025年3月完成。

干预措施：参与者按1:1比例随机分配至闭环治疗组（n=46）或标准治疗组（胰岛素泵或每日多次胰岛素注射）（n=45），两组均使用连续血糖监测。

主要结局指标：主要结局为妊娠16至34周期间，通过连续血糖监测测量的处于妊娠特异性血糖范围（63-140 mg/dL）的时间百分比。

结果：在94名入组参与者中，3名在随机分组前发生妊娠丢失，91名被随机分组（平均年龄31.7[SD, 5.2]岁；早孕期糖化血红蛋白7.4%[SD, 1.0%]），88名纳入主要分析。妊娠16至34周期间，闭环组处于妊娠特异性血糖范围的平均时间为65.4%，标准治疗组为50.3%（平均调整差异为12.5[95% CI, 9.5-15.6]个百分点；P<.001）。闭环组发生1次严重低血糖事件，闭环组发生2次糖尿病酮症酸中毒事件，标准治疗组发生1次。

结论和相关性：使用闭环系统的1型糖尿病孕妇处于妊娠特异性血糖范围的时间显著长于接受标准治疗的孕妇。这些发现支持在1型糖尿病孕妇中使用该闭环系统。

试验注册：ClinicalTrials.gov标识符：NCT04902378。

### 第二部分 AI 大师评价

本研究是一项重要的多中心随机临床试验，旨在评估闭环胰岛素系统在妊娠期1型糖尿病中的疗效。研究设计严谨，在加拿大和澳大利亚的14个临床中心开展，纳入91名参与者并随访至产后6周。关键发现显示，闭环系统显著提高了患者处于妊娠特异性血糖范围的时间（65.4% vs 50.3%），差异达12.5个百分点。这一创新技术填补了妊娠期糖尿病管理的重要空白，具有显著的临床价值，有望降低50%的高血糖相关妊娠并发症风险。然而，研究也观察到闭环组出现2例糖尿病酮症酸中毒事件，提示在推广应用中需要关注安全性监测。

---

## 7. COVID-19与甲型流感患者在接受静脉-静脉体外膜肺氧合治疗中的急性脑损伤：基于体外生命支持组织注册登记的倾向评分匹配分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41134089](https://pubmed.ncbi.nlm.nih.gov/41134089)
**期刊：** Critical care medicine
**PMID：** 41134089
**DOI：** 10.1097/CCM.0000000000006916

### 第一部分 原文与翻译

**英文原标题：** Acute Brain Injury in COVID-19 Versus Influenza A Patients on Venovenous Extracorporeal Membrane Oxygenation: A Propensity Score Matching Analysis of the Extracorporeal Life Support Organization Registry.

**英文摘要原文：**
OBJECTIVES: Limited data exist on outcomes in COVID-19- vs. influenza A (H1N1)-associated acute respiratory distress syndrome (ARDS) patients when supported on venovenous extracorporeal membrane oxygenation (ECMO). We aimed to compare acute brain injury (ABI) frequency, thrombotic, and hemorrhagic complications and mortality in COVID-19- vs. H1N1-associated ARDS patients on venovenous ECMO.

DESIGN: Retrospective multicenter observational cohort study.

SETTING: Data reported to the Extracorporeal Life Support Organization by up to 534 ECMO centers from 2009 to 2021.

PATIENTS: Patients 18 years or older with COVID-19 or H1N1 requiring venovenous ECMO support.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: We conducted a retrospective analysis on 2253 venovenous ECMO patients (1916 COVID-19 and 337 H1N1). We employed propensity score matching followed by multivariable logistic regression to compare outcomes. The primary outcome was ABI and secondary outcomes were thrombosis, hemorrhage, and mortality. After matching, 674 patients (337 COVID and 337 H1N1) remained (median age = 41, 55% male). In the matched cohort, 10% of COVID-19 patients experienced ABI compared with 12% of H1N1 patients, with no significant difference between the groups (adjusted odds ratio [aOR], 0.83; 95% CI, 0.44-1.54; p = 0.53). There was no difference in thrombotic complications (aOR, 0.67; 95% CI, 0.44-1.02; p = 0.06), but COVID-19 patients had fewer hemorrhagic complications (aOR, 0.27; 95% CI, 0.17-0.42; p < 0.001) compared with H1N1. Mortality was higher in COVID patients (aOR, 2.17; 95% CI, 1.45-3.23; p < 0.001). In both groups, however, patients with ABI had higher mortality than those without, with 94% vs. 40% (p < 0.001) for COVID and 75% vs. 29% (p < 0.001) for H1N1, respectively.

CONCLUSIONS: COVID-19 and H1N1 patients on venovenous ECMO exhibited similar ABI frequency, which was twice that observed in the general historical ARDS patients supported on venovenous ECMO population. Our findings highlight that both COVID and H1N1 ARDS increase ABI frequency in ECMO patients. Finally, the presence of ABI doubled mortality among both COVID and H1N1.

**中文摘要译文：**
目的：关于COVID-19与甲型流感（H1N1）相关急性呼吸窘迫综合征（ARDS）患者在接受静脉-静脉体外膜肺氧合（ECMO）支持时结局的数据有限。我们旨在比较COVID-19与H1N1相关ARDS患者在接受静脉-静脉ECMO治疗时的急性脑损伤（ABI）发生率、血栓性和出血性并发症以及死亡率。

设计：回顾性多中心观察性队列研究。

背景：2009年至2021年间，由多达534个ECMO中心向体外生命支持组织报告的数据。

患者：年龄18岁及以上、需要静脉-静脉ECMO支持的COVID-19或H1N1患者。

干预措施：无。

测量与主要结果：我们对2253例静脉-静脉ECMO患者（1916例COVID-19和337例H1N1）进行了回顾性分析。我们采用倾向评分匹配后进行多变量逻辑回归来比较结局。主要结局是ABI，次要结局是血栓形成、出血和死亡率。匹配后，剩余674例患者（337例COVID和337例H1N1）（中位年龄=41岁，55%为男性）。在匹配队列中，10%的COVID-19患者发生ABI，而H1N1患者为12%，两组间无显著差异（调整后比值比[aOR]，0.83；95% CI，0.44-1.54；p = 0.53）。血栓并发症无差异（aOR，0.67；95% CI，0.44-1.02；p = 0.06），但COVID-19患者的出血并发症少于H1N1患者（aOR，0.27；95% CI，0.17-0.42；p < 0.001）。COVID患者的死亡率更高（aOR，2.17；95% CI，1.45-3.23；p < 0.001）。然而，在两组中，ABI患者的死亡率均高于无ABI患者，COVID组分别为94% vs. 40%（p < 0.001），H1N1组分别为75% vs. 29%（p < 0.001）。

结论：接受静脉-静脉ECMO治疗的COVID-19和H1N1患者表现出相似的ABI发生率，这是传统静脉-静脉ECMO支持的普通ARDS患者人群观察到的两倍。我们的研究结果强调，COVID和H1N1 ARDS均会增加ECMO患者的ABI发生率。最后，ABI的存在使COVID和H1N1患者的死亡率均翻倍。

### 第二部分 AI 大师评价

本研究通过回顾性分析体外生命支持组织注册登记的大规模数据，采用倾向评分匹配方法系统比较了COVID-19与H1N1相关ARDS患者在ECMO支持下的神经系统并发症和临床结局。研究创新性地揭示了两种病毒性肺炎在ECMO治疗中具有相似的急性脑损伤发生率（约10-12%），且这一发生率是传统ARDS患者的两倍。尽管COVID-19患者出血并发症较少，但其总体死亡率显著高于H1N1患者，而急性脑损伤的存在使两种疾病患者的死亡率均显著增加。该研究为重症病毒性肺炎ECMO治疗中的神经系统风险评估提供了重要循证依据，但由于其回顾性设计，仍需前瞻性研究进一步验证这些发现。

---

## 8. 利福平暴露和临床基线协变量对肺结核治疗反应作用机制的深入解析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41133922](https://pubmed.ncbi.nlm.nih.gov/41133922)
**期刊：** Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
**PMID：** 41133922
**DOI：** 10.1093/cid/ciaf586

### 第一部分 原文与翻译

**英文原标题：** Insights into the Role of Rifampicin Exposure and Clinical Baseline Covariates on the Response to Pulmonary Tuberculosis Treatment.

**英文摘要原文：**
BACKGROUND: Quantitative markers of tuberculosis disease burden are essential for assessing treatment response and optimizing therapeutic strategies. This study evaluated the impact of antimicrobial plasma drug levels on time-to-positivity (TTP) trajectories in patients with drug-susceptible tuberculosis and explored the relationship between bacillary clearance and treatment outcomes.

METHODS: Patients with drug susceptible pulmonary tuberculosis initiating treatment were recruited in Worcester, South Africa. Weekly sputum samples were collected for 12 weeks, with bacterial load quantified using Mycobacterial Growth Indicator Tubes, yielding TTP. Nonlinear mixed-effects modeling was used to empirically describe longitudinal TTP, assessing rifampicin exposure and other participant characteristics as covariates. TTP trajectories were stratified by treatment outcomes to identify trends between change in TTP and outcome.

RESULTS: 402 participants were included, of whom 60% were male. Median age was 37 years (IQR 26-48) and 90% had successful treatment outcomes (were cured or completed treatment) at 6 months with 3% who experienced treatment failure, 2% died, 1% transferred and 4% were lost to follow-up. Baseline smear grade and lung cavitation decreased baseline TTP. Higher rifampicin concentration area under the curve (AUC) was associated with faster longitudinal change in TTP, while lung cavitation and older age were associated with slower longitudinal change. Further, slower change in TTP during the first 12 weeks of treatment was linked to treatment failure at six months.

CONCLUSION: Our findings highlight the role of rifampicin plasma exposure in optimizing bacillary clearance and improving treatment outcomes, even within standard dosing regimens for drug-susceptible tuberculosis.

**中文摘要译文：**
背景：结核病疾病负担的定量标志物对于评估治疗反应和优化治疗策略至关重要。本研究评估了抗微生物血浆药物水平对药物敏感结核病患者阳性时间轨迹的影响，并探讨了细菌清除与治疗结果之间的关系。

方法：在南非伍斯特招募了开始治疗的药物敏感肺结核患者。连续12周每周收集痰液样本，使用分枝杆菌生长指示管定量细菌负荷，获得阳性时间。采用非线性混合效应模型经验性地描述纵向阳性时间，评估利福平暴露和其他参与者特征作为协变量。根据治疗结果对阳性时间轨迹进行分层，以识别阳性时间变化与结果之间的趋势。

结果：共纳入402名参与者，其中60%为男性。中位年龄为37岁（四分位距26-48），90%在6个月时有成功的治疗结果（治愈或完成治疗），其中3%经历治疗失败，2%死亡，1%转诊，4%失访。基线涂片等级和肺部空洞降低了基线阳性时间。较高的利福平浓度曲线下面积与更快的纵向阳性时间变化相关，而肺部空洞和年龄较大与较慢的纵向变化相关。此外，治疗前12周阳性时间变化较慢与六个月时的治疗失败相关。

结论：我们的研究结果强调了利福平血浆暴露在优化细菌清除和改善治疗结果中的作用，即使在药物敏感结核病的标准给药方案内也是如此。

### 第二部分 AI 大师评价

本研究通过定量分析利福平血浆暴露与细菌清除动力学的关系，为结核病治疗优化提供了重要见解。研究创新性地采用非线性混合效应模型分析阳性时间轨迹，发现利福平曲线下面积与细菌清除速度呈正相关，而肺部空洞和年龄是影响清除速度的负面因素。该研究具有显著的临床价值，首次明确证明治疗早期阳性时间变化速率可作为预测治疗失败的生物标志物，为个体化治疗调整提供了科学依据。然而，研究局限于南非单一中心，未来需要多中心验证以增强结果的普适性。

---

## 9. B细胞清除疗法免疫抑制患者使用尼马曲韦/利托那韦或莫努匹拉韦治疗COVID-19的有效性：一项目标试验模拟研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41132135](https://pubmed.ncbi.nlm.nih.gov/41132135)
**期刊：** Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
**PMID：** 41132135
**DOI：** 10.1093/cid/ciaf521

### 第一部分 原文与翻译

**英文原标题：** Effectiveness of Nirmatrelvir/Ritonavir or Molnupiravir Use in Immunocompromised Patients on B-Cell-Depleting Therapy With COVID-19: A Target Trial Emulation Study.

**英文摘要原文：**
BACKGROUND: Immunocompromised patients, especially those receiving B-cell-depleting therapy (BCDT), remain at high risk for severe coronavirus disease 2019 (COVID-19). Although monoclonal antibodies showed benefit pre-Omicron, the real-world effectiveness of the oral antivirals in BCDT recipients is unclear.

METHODS: We emulated a target trial using the Cleveland Clinic electronic health record. Adult patients (≥18 years) with immune-mediated inflammatory diseases who received rituximab or ocrelizumab and tested positive for severe acute respiratory syndrome coronavirus 2 between 19 December 2021 and 30 June 2025 were eligible. The primary endpoint was hospitalization or death within 21 days; the secondary endpoint was death within 90 days. Propensity scores adjusted for confounding, and Weighted Cox regression models were used to evaluated treatment effects.

RESULTS: Among 255 853 COVID-19 cases, 876 met criteria for the nirmatrelvir/ritonavir cohort (411 treated, 465 untreated) and 566 for the molnupiravir cohort (91 treated, 475 untreated). In the nirmatrelvir/ritonavir cohort, 18 (4.4%) of treated versus 43 (9.2%) of untreated patients were hospitalized or died within 21 days. After weighting, nirmatrelvir/ritonavir reduced the hazard by 44% (hazard ratio [HR], 0.56; 95% confidence interval [CI],  0.31-0.99). In the molnupiravir cohort, 6 (6.6%) of treated and 46 (9.7%) of untreated patients met the primary endpoint; the weighted HR was 0.56 (95% CI, 0.24-1.33), not statistically significant.

CONCLUSIONS: Early outpatient nirmatrelvir/ritonavir significantly lowers the risk of COVID-19-related hospitalization or death in patients on BCDT. Molnupiravir showed a nonsignificant trend toward benefit. These findings support prioritizing nirmatrelvir/ritonavir for high-risk immunocompromised populations.

**中文摘要译文：**
背景：免疫抑制患者，特别是接受B细胞清除疗法（BCDT）的患者，仍然是重症2019冠状病毒病（COVID-19）的高危人群。尽管单克隆抗体在奥密克戎变异株出现前显示出益处，但口服抗病毒药物在BCDT接受者中的真实世界有效性尚不清楚。

方法：我们使用克利夫兰诊所电子健康记录模拟了一项目标试验。纳入标准为患有免疫介导性炎症疾病、接受利妥昔单抗或奥瑞珠单抗治疗，并在2021年12月19日至2025年6月30日期间严重急性呼吸综合征冠状病毒2检测呈阳性的成年患者（≥18岁）。主要终点为21天内住院或死亡；次要终点为90天内死亡。使用倾向评分调整混杂因素，并采用加权Cox回归模型评估治疗效果。

结果：在255,853例COVID-19病例中，876例符合尼马曲韦/利托那韦队列标准（411例接受治疗，465例未治疗），566例符合莫努匹拉韦队列标准（91例接受治疗，475例未治疗）。在尼马曲韦/利托那韦队列中，治疗组有18例（4.4%）与未治疗组43例（9.2%）在21天内住院或死亡。加权后，尼马曲韦/利托那韦使风险降低了44%（风险比[HR]，0.56；95%置信区间[CI]，0.31-0.99）。在莫努匹拉韦队列中，治疗组6例（6.6%）和未治疗组46例（9.7%）达到主要终点；加权HR为0.56（95% CI，0.24-1.33），无统计学显著性。

结论：早期门诊使用尼马曲韦/利托那韦显著降低了接受BCDT治疗患者COVID-19相关住院或死亡的风险。莫努匹拉韦显示出无统计学显著性的获益趋势。这些发现支持将尼马曲韦/利托那韦优先用于高危免疫抑制人群。

### 第二部分 AI 大师评价

本研究采用目标试验模拟方法，评估了两种口服抗病毒药物在B细胞清除疗法免疫抑制患者中的真实世界有效性。研究创新性地利用大规模电子健康记录数据，通过倾向评分和加权Cox回归模型控制混杂因素，为这一特殊高危人群提供了重要的临床证据。关键发现显示尼马曲韦/利托那韦可使住院或死亡风险显著降低44%，而莫努匹拉韦虽显示获益趋势但未达统计学显著性。该研究具有重要的临床指导价值，为免疫抑制患者的抗病毒药物选择提供了循证依据，但研究存在观察性设计的固有局限性，且莫努匹拉韦组样本量相对较小可能影响统计效能。

---

## 10. 院外心脏骤停患者家属心理症状的一年轨迹研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41131609](https://pubmed.ncbi.nlm.nih.gov/41131609)
**期刊：** Critical care (London, England)
**PMID：** 41131609
**DOI：** 10.1186/s13054-025-05643-w

### 第一部分 原文与翻译

**英文原标题：** One-year trajectory of psychological symptoms in families of out-of-hospital cardiac arrest patients.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究聚焦于院外心脏骤停患者家属的心理健康轨迹，通过为期一年的纵向随访，系统评估家属群体在患者经历心脏骤停后的心理症状演变规律。该研究填补了心脏骤停领域对家属长期心理影响的认知空白，具有重要的临床实践价值，可为制定针对性的心理干预方案提供循证依据。然而，由于摘要信息缺失，无法深入了解具体的研究设计、样本特征和关键发现，期待全文发表后能更全面地评估其方法学严谨性和结果可靠性。

---

## 11. 吸入性聚乙二醇化肾上腺髓质素在ARDS患者中的安全性和有效性：一项随机对照试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41131549](https://pubmed.ncbi.nlm.nih.gov/41131549)
**期刊：** Critical care (London, England)
**PMID：** 41131549
**DOI：** 10.1186/s13054-025-05617-y

### 第一部分 原文与翻译

**英文原标题：** Safety and efficacy of inhaled PEG-ADM in ARDS patients: a randomised controlled trial.

**英文摘要原文：**
BACKGROUND: This study aimed to evaluate the safety and efficacy of inhaled pegylated adrenomedullin (PEG-ADM) for the management of acute respiratory distress syndrome in critically ill patients on mechanical ventilation.

METHODS: A Phase 2a/b randomised, double-blind, placebo-controlled multicentre trial was conducted. Patients with acute respiratory distress syndrome were assigned to receive PEG-ADM 960 μg or 1920 μg, or placebo. The primary endpoints were safety, efficacy, and ventilator-free survival at Day 28. Efficacy was assessed using ventilator-free survival and the clinical utility index, a composite endpoint that includes extravascular lung water index, oxygenation index, non-pulmonary Sequential Organ Failure Assessment score.

RESULTS: Ninety patients were randomised (PEG-ADM 960 μg: n = 29; PEG-ADM 1920 μg: n = 30; placebo: n = 31). Both dosages of PEG-ADM were well tolerated, with adverse event profiles similar to placebo. However, no significant efficacy was observed on the clinical utility index. Ventilator-free survival at Day 28 was lower in the PEG-ADM 960 μg group (52%) compared with the PEG-ADM 1920 μg (67%) and placebo (65%) groups. No significant differences were noted in overall mortality or the need for continued ventilation at Days 28 and 60.

CONCLUSION: Inhaled PEG-ADM was well tolerated in patients with acute respiratory distress syndrome, but it did not improve clinical outcomes, which led to the early discontinuation after the first part of the trial for futility.

TRIAL REGISTRATION: ClinicalTrials.gov: NCT04417036 (date of registration: 4 June 2020).

**中文摘要译文：**
背景：本研究旨在评估吸入性聚乙二醇化肾上腺髓质素（PEG-ADM）用于管理接受机械通气的危重症患者急性呼吸窘迫综合征的安全性和有效性。

方法：进行了一项2a/b期随机、双盲、安慰剂对照的多中心试验。急性呼吸窘迫综合征患者被分配接受PEG-ADM 960 μg或1920 μg，或安慰剂。主要终点是安全性、有效性以及第28天的无呼吸机生存率。有效性通过无呼吸机生存率和临床效用指数进行评估，后者是一个复合终点，包括血管外肺水指数、氧合指数、非肺部序贯器官衰竭评估评分。

结果：共90例患者被随机分组（PEG-ADM 960 μg组：n=29；PEG-ADM 1920 μg组：n=30；安慰剂组：n=31）。两种剂量的PEG-ADM均耐受良好，不良事件特征与安慰剂相似。然而，在临床效用指数方面未观察到显著的有效性。PEG-ADM 960 μg组第28天的无呼吸机生存率（52%）低于PEG-ADM 1920 μg组（67%）和安慰剂组（65%）。在第28天和第60天，总体死亡率或持续通气需求方面未发现显著差异。

结论：吸入性PEG-ADM在急性呼吸窘迫综合征患者中耐受良好，但未能改善临床结局，这导致试验第一部分因无效而提前终止。

试验注册：ClinicalTrials.gov：NCT04417036（注册日期：2020年6月4日）。

### 第二部分 AI 大师评价

本研究是一项针对急性呼吸窘迫综合征（ARDS）的创新性治疗探索，采用随机双盲对照设计评估吸入性聚乙二醇化肾上腺髓质素（PEG-ADM）的安全性和有效性。研究创新性地通过吸入给药途径靶向肺部病理生理过程，体现了精准治疗理念。然而，尽管药物表现出良好的安全性特征，但在主要有效性终点上未能证明优于安慰剂，甚至低剂量组无呼吸机生存率反而更低，这提示该治疗策略在ARDS管理中的临床价值有限。该阴性结果对于指导后续研究方向具有重要意义，强调了ARDS复杂病理机制下单一靶点干预的挑战性，也为同类药物开发提供了重要参考。

---

## 12. 肠道上皮细胞中CARD14信号传导诱导肠道炎症和肠道传输延迟

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41131424](https://pubmed.ncbi.nlm.nih.gov/41131424)
**期刊：** EMBO molecular medicine
**PMID：** 41131424
**DOI：** 10.1038/s44321-025-00321-4

### 第一部分 原文与翻译

**英文原标题：** CARD14 signaling in intestinal epithelial cells induces intestinal inflammation and intestinal transit delay.

**英文摘要原文：**
CARD14 is an intracellular NF-κB signaling mediator in the skin, and rare CARD14 variants have been associated with psoriasis and atopic dermatitis. CARD14 is also expressed in intestinal epithelial cells (IEC). However, its function in the intestine remains unknown. We demonstrate here that transgenic mice expressing the psoriasis-associated gain-of-function human CARD14(E138A) mutant specifically in IEC show mild intestinal inflammation, without epithelial damage. Moreover, CARD14(E138A) mice show a drastic reduction in intestinal motility, often associated with rectal prolapse. Enteric neuronal survival and functionality are unaffected in CARD14(E138A) mice. Transcriptome analysis of IEC from CARD14(E138A) mice reveals decreased expression of antimicrobial peptides by Paneth cells, accompanied by microbial dysbiosis and increased susceptibility to enteric bacterial infection. Our findings suggest that gain-of-function CARD14 mutations may not only predispose patients to psoriasis but also mild intestinal inflammation, reduced intestinal motility, and increased sensitivity to intestinal infection. CARD14(E138A) mice are also a valuable tool for further investigation of IEC-intrinsic molecular processes involved in intestinal inflammation and motility disorders.

**中文摘要译文：**
CARD14是皮肤中细胞内NF-κB信号传导介质，罕见的CARD14变异与银屑病和特应性皮炎相关。CARD14也在肠道上皮细胞（IEC）中表达。然而，其在肠道中的功能仍然未知。我们在此证明，在IEC中特异性表达与银屑病相关的功能获得性人类CARD14(E138A)突变体的转基因小鼠表现出轻度肠道炎症，但无上皮损伤。此外，CARD14(E138A)小鼠显示出肠道运动能力的急剧下降，通常伴有直肠脱垂。CARD14(E138A)小鼠的肠道神经元存活和功能未受影响。对CARD14(E138A)小鼠IEC的转录组分析显示，潘氏细胞抗菌肽表达减少，伴随微生物失调和对肠道细菌感染的易感性增加。我们的发现表明，功能获得性CARD14突变可能不仅使患者易患银屑病，还可能导致轻度肠道炎症、肠道运动能力降低和对肠道感染的敏感性增加。CARD14(E138A)小鼠也是进一步研究涉及肠道炎症和运动障碍的IEC内在分子过程的有价值工具。

### 第二部分 AI 大师评价

本研究通过构建特异性表达功能获得性CARD14(E138A)突变体的转基因小鼠模型，首次系统揭示了CARD14在肠道上皮细胞中的生理功能。研究采用转录组分析等先进技术，发现该突变导致潘氏细胞抗菌肽表达下降、肠道菌群失调和肠道运动障碍，但不影响肠道神经元功能。这一发现具有重要创新性，将皮肤免疫相关蛋白CARD14的功能扩展至肠道领域，为理解肠道炎症和运动障碍的分子机制提供了新视角。该研究不仅揭示了CARD14突变可能同时影响皮肤和肠道健康，还为开发相关疾病治疗策略提供了重要实验模型，但需进一步验证这些发现在人类患者中的临床相关性。

---

## 13. 通过原位冷冻电子断层扫描可视化甲型流感病毒组装过程

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41130956](https://pubmed.ncbi.nlm.nih.gov/41130956)
**期刊：** Nature communications
**PMID：** 41130956
**DOI：** 10.1038/s41467-025-65117-z

### 第一部分 原文与翻译

**英文原标题：** Visualizing influenza A virus assembly by in situ cryo-electron tomography.

**英文摘要原文：**
Influenza A virus (IAV) forms pleomorphic particles that package eight ribonucleoprotein complexes (vRNPs), each carrying a distinct RNA genome segment. vRNPs assemble in the nucleus and undergo selective sorting during Rab11a-mediated trafficking to the plasma membrane. Virion assembly is orchestrated by matrix protein 1 (M1), which forms a layer beneath the viral envelope containing hemagglutinin (HA) and neuraminidase (NA). However, molecular details of vRNP distribution, cytosolic trafficking, and coordination of IAV assembly remains unclear. Using in situ cryo-ET, we reveal that HA-containing membranes provide Rab11a-dependent platforms for membrane-assisted vRNP clustering, reducing inter-vRNP distances. In the absence of HA, vRNPs cluster on NA-containing membranes and virus assembly remains intact, indicating that vRNP clustering and trafficking is membrane-assisted but HA independent. The characteristic 7 + 1 vRNP bundle forms concomitantly with budding and is orchestrated by M1 layer assembly that precedes plasma membrane attachment. We further reveal that intracellular M1 forms multilayered helical assemblies of antiparallel dimers, structurally distinct from the M1 layer in virions. These assemblies are compact in the nucleus but partially dissociate in the cytoplasm, likely serving as a reservoir for budding. Together, our findings uncover membrane-assisted vRNP clustering and molecular details of M1 coordinated influenza virus assembly.

**中文摘要译文：**
甲型流感病毒（IAV）形成多形性颗粒，包装八个核糖核蛋白复合物（vRNPs），每个复合物携带一个不同的RNA基因组片段。vRNPs在细胞核中组装，并在Rab11a介导的向质膜运输过程中进行选择性分选。病毒颗粒组装由基质蛋白1（M1）协调，该蛋白在包含血凝素（HA）和神经氨酸酶（NA）的病毒包膜下方形成一层。然而，vRNP分布、胞质运输和IAV组装协调的分子细节仍不清楚。通过使用原位冷冻电子断层扫描，我们发现含HA的膜提供了Rab11a依赖的平台，用于膜辅助的vRNP聚集，减少了vRNP之间的距离。在缺乏HA的情况下，vRNPs在含NA的膜上聚集，病毒组装仍然完整，表明vRNP聚集和运输是膜辅助的但不依赖于HA。特征性的7+1 vRNP束在出芽过程中同时形成，并由先于质膜附着的M1层组装协调。我们进一步发现细胞内M1形成多层螺旋组装体，由反向平行二聚体组成，在结构上不同于病毒颗粒中的M1层。这些组装体在细胞核中紧密，但在细胞质中部分解离，可能作为出芽的储备库。总之，我们的发现揭示了膜辅助的vRNP聚集和M1协调流感病毒组装的分子细节。

### 第二部分 AI 大师评价

本研究采用原位冷冻电子断层扫描技术，首次在近生理状态下揭示了甲型流感病毒组装的分子机制。核心发现包括：膜辅助的vRNP聚集机制、M1蛋白在病毒组装中的关键协调作用，以及细胞内M1形成与病毒颗粒中结构不同的多层螺旋组装体。该研究的创新性在于突破了传统体外研究的局限，提供了病毒组装过程的实时可视化证据，为理解流感病毒生命周期和开发新型抗病毒策略提供了重要理论基础。虽然研究主要聚焦于基础机制，但其揭示的M1蛋白动态结构变化可能为靶向病毒组装的药物设计开辟新途径。

---

## 14. 遗传学和社会健康决定因素作为结节病流行病学变异的驱动因素

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41130282](https://pubmed.ncbi.nlm.nih.gov/41130282)
**期刊：** Seminars in respiratory and critical care medicine
**PMID：** 41130282
**DOI：** 10.1055/a-2724-5501

### 第一部分 原文与翻译

**英文原标题：** Genetics and social determinants of health as drivers of epidemiologic variation in sarcoidosis.

**英文摘要原文：**
Sarcoidosis is a disease with high morbidity that has variable epidemiology based on genetics and sociodemographic factors. The etiology of this variability remains incompletely understood. This narrative review describes how genetics, social determinants of health, and the interactions between them may contribute to the differences in epidemiology and health outcomes observed in different patient groups with sarcoidosis.

**中文摘要译文：**
结节病是一种高发病率疾病，其流行病学特征因遗传学和社会人口学因素而异。这种变异性的病因学尚未完全阐明。本叙述性综述描述了遗传学、社会健康决定因素以及它们之间的相互作用如何可能导致在不同结节病患者群体中观察到的流行病学和健康结局差异。

### 第二部分 AI 大师评价

本研究通过叙述性综述方法，深入探讨了遗传学和社会健康决定因素在结节病流行病学变异中的关键作用。该研究创新性地将遗传因素与社会环境因素相结合，揭示了二者相互作用对疾病表现和预后的影响机制。这一研究具有重要的临床价值，为理解结节病的异质性提供了新的理论框架，并为制定个体化防治策略奠定了基础。然而，作为综述性研究，其局限性在于主要基于现有文献分析，需要更多原始研究来验证这些相互作用机制。

---

## 15. 弥漫性肺泡出血（DAH）

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41130281](https://pubmed.ncbi.nlm.nih.gov/41130281)
**期刊：** Seminars in respiratory and critical care medicine
**PMID：** 41130281
**DOI：** 10.1055/a-2725-7274

### 第一部分 原文与翻译

**英文原标题：** Diffuse Alveolar Hemorrhage (DAH).

**英文摘要原文：**
Diffuse Alveolar Hemorrhage (DAH) is a life-threatening clinical syndrome characterized by bleeding from the pulmonary microcirculation into alveolar spaces. It typicially presents with acute respiratory failure, anemia, and diffuse radiological infiltrates. Importantly hemoptysis may be absent in up to half of cases. Etiologies are diverse, encompassing systemic vasculitides, connective tissue diseases, coagulopathies, drugs, infections, hemodynamic disturbances, and idiopathic processes. Histopathologically, DAH manifests as one of three overlapping patterns: pulmonary capillaritis, bland alveolar hemorrhage, or diffuse alveolar damage, which help guide diagnostic and therapeutic strategies. Capillaritis, commonly associated with immune-mediated vasculitis such as ANCA-associated vasculitis and anti-glomerular basement membrane disease, typically necessitating prompt and aggressive immunosuppression. In contrast, bland hemorrhage often reflects coagulopathy or hemodynamic factors, while diffuse alveolar damage is linked to toxins, infections, or ARDS. Prompt recognition and systematic evaluation are critical to optimizing outcomes, given DAH's high in-hospital mortality exceeding 20%. Diagnosis relies on a combination of imaging, bronchoalveolar lavage (demonstrating progressively bloodier returns and hemosiderin-laden macrophages), and targeted laboratory evaluation for vasculitis, infection, and coagulopathy. Management includes patient stabilization with supplementary oxygen or indeed ventilatory support, careful avoidance of ventilator-induced lung injury, and etiology-directed therapy. High-dose corticosteroids, cytotoxic agents, and rituximab remain central in immune-mediated cases, while plasma exchange is indicated in anti-GBM disease and severe refractory hemoptysis. Antimicrobial therapy, drug withdrawal, hemostatic interventions, and, in select cases, extracorporeal support may also be required. This review outlines the histopathological spectrum, etiologic categories, diagnostic algorithms, and evidence-based therapeutic approaches to DAH, emphasizing the importance of early multidisciplinary management to improve survival and functional recovery.

**中文摘要译文：**
弥漫性肺泡出血（DAH）是一种危及生命的临床综合征，其特征是肺微循环出血进入肺泡腔。它通常表现为急性呼吸衰竭、贫血和弥漫性影像学浸润。重要的是，高达一半的病例可能没有咯血。病因多样，包括系统性血管炎、结缔组织病、凝血功能障碍、药物、感染、血流动力学紊乱和特发性过程。组织病理学上，DAH表现为三种重叠模式之一：肺毛细血管炎、单纯肺泡出血或弥漫性肺泡损伤，这有助于指导诊断和治疗策略。毛细血管炎通常与免疫介导的血管炎相关，如ANCA相关性血管炎和抗肾小球基底膜病，通常需要及时和积极的免疫抑制治疗。相比之下，单纯出血通常反映凝血功能障碍或血流动力学因素，而弥漫性肺泡损伤与毒素、感染或ARDS相关。考虑到DAH的院内死亡率超过20%，及时识别和系统评估对于优化预后至关重要。诊断依赖于影像学、支气管肺泡灌洗（显示逐渐血性回收液和含铁血黄素巨噬细胞）以及针对血管炎、感染和凝血功能障碍的有针对性实验室评估的综合应用。管理包括通过补充氧气或机械通气支持稳定患者，谨慎避免呼吸机相关性肺损伤，以及病因导向治疗。大剂量皮质类固醇、细胞毒性药物和利妥昔单抗在免疫介导的病例中仍然是核心治疗，而血浆置换适用于抗GBM病和严重难治性咯血。抗微生物治疗、停药、止血干预以及在特定病例中的体外支持也可能需要。本综述概述了DAH的组织病理学谱系、病因分类、诊断流程和循证治疗方法，强调了早期多学科管理对于提高生存率和功能恢复的重要性。

### 第二部分 AI 大师评价

本研究系统综述了弥漫性肺泡出血（DAH）这一危重症的全面诊疗策略，具有重要的临床指导价值。研究通过整合影像学、支气管肺泡灌洗和实验室检查构建了系统的诊断流程，并基于组织病理学模式（毛细血管炎、单纯出血、弥漫性肺泡损伤）建立了精准的治疗框架。关键发现包括高达50%病例无咯血表现、超过20%的院内死亡率以及基于病因的个体化治疗方案。该综述的创新性在于将复杂的病理机制与临床实践紧密结合，为这一高死亡率疾病提供了循证医学指导。虽然作为综述性文章缺乏原始研究数据，但其临床实用价值显著，对改善DAH患者预后具有重要指导意义。

---

## 16. HIV感染患者的肺部感染

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41130280](https://pubmed.ncbi.nlm.nih.gov/41130280)
**期刊：** Seminars in respiratory and critical care medicine
**PMID：** 41130280
**DOI：** 10.1055/a-2725-7350

### 第一部分 原文与翻译

**英文原标题：** Pulmonary Infections in HIV patients.

**英文摘要原文：**
Pulmonary infection is an important cause of hospitalization, morbidity, and mortality in people living with human immunodeficiency virus (PWH) infection, especially in those with significant immunosuppression. Pneumonia, including Pneumocystis jirovecii and Mycobacterium tuberculosis etiologies, continue to be the most frequent pulmonary infections in PWH. However, identifying the etiology of pulmonary infection in PWH is challenging because of the overlap in clinical features and the frequency of co-infection. This review focuses on the current scientific evidence regarding pulmonary infection in PWH, including its epidemiology, clinical presentation, diagnosis, and management.

**中文摘要译文：**
肺部感染是人类免疫缺陷病毒（PWH）感染者住院、发病和死亡的重要原因，特别是在免疫功能严重抑制的患者中。肺炎，包括耶氏肺孢子菌和结核分枝杆菌等病原体引起的感染，仍然是PWH患者中最常见的肺部感染。然而，由于临床表现的重叠性和合并感染的频率较高，识别PWH患者肺部感染的病因具有挑战性。本综述重点关注当前关于PWH患者肺部感染的科学证据，包括其流行病学、临床表现、诊断和治疗。

### 第二部分 AI 大师评价

本研究系统综述了HIV感染者肺部感染的临床特征与管理策略。通过文献回顾方法，明确了耶氏肺孢子菌肺炎和结核分枝杆菌感染是HIV患者最常见的肺部感染类型，并强调了临床表现重叠和合并感染对病因诊断的挑战。该研究的创新性在于全面整合了当前关于HIV相关肺部感染的流行病学、诊断和治疗的最新证据，具有重要的临床指导价值。然而，作为综述性研究，其局限性在于缺乏原始数据支持，未来需要更多前瞻性研究来验证相关结论。

---

## 17. 免疫功能受损患者呼吸衰竭中的无创通气

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41130271](https://pubmed.ncbi.nlm.nih.gov/41130271)
**期刊：** Seminars in respiratory and critical care medicine
**PMID：** 41130271
**DOI：** 10.1055/a-2709-6808

### 第一部分 原文与翻译

**英文原标题：** Non-Invasive Ventilation in Immunocompromised Patients with Respiratory Failure.

**英文摘要原文：**
Non-invasive ventilation (NIV) is commonly recommended as respiratory support for selected immunocompromised patients with acute respiratory failure (ARF), offering an alternative to tracheal intubation, which historically carried high mortality rates in this population. Initial enthusiasm for NIV stemmed from its potential to avoid invasive ventilation. However, evolving evidence has demonstrated a gradual reduction in mortality among intubated immunocompromised patients, attributed to advances in oncologic therapies, improvements in intensive care unit (ICU) management, and refined triage criteria. These findings have led to a reassessment of NIV's role in this context, suggesting that immunocompromised patients with ARF may benefit from treatment strategies similar to those used in the general population, including timely intubation when clinically indicated. Notably, survival outcomes remain influenced by inconsistent intubation criteria across studies, underlying causes of immunosuppression, and patient severity. Recent studies also highlight poor ICU outcomes in patients with specific oncohematologic profiles and fragile physical states, tempering enthusiasm for invasive support in these subgroups. Identifying predictors of NIV failure is critical to guide ventilation strategies in immunocompromised patients with ARF and determine when ongoing non-invasive support may become counterproductive. However, since there are no validated tools to predict the success or failure of NIV in these patients, careful bedside assessment of their response to non-invasive strategies is essential to ensure timely intubation and prevent dangerous delays in those who do not show signs of improvement. After the widespread adoption of NIV, the introduction of high-flow nasal cannula oxygenation has emerged as a new tool in managing specific scenarios of respiratory failure, playing a central role in influencing the prognosis of critically ill patients. Its effectiveness has also been investigated in immunocompromised patients.

**中文摘要译文：**
无创通气（NIV）通常被推荐作为选定的免疫功能受损患者急性呼吸衰竭（ARF）的呼吸支持手段，为气管插管提供了替代方案，而气管插管在该人群中历史上具有较高的死亡率。最初对NIV的热情源于其避免有创通气的潜力。然而，不断发展的证据表明，插管的免疫功能受损患者的死亡率逐渐降低，这归因于肿瘤治疗的进步、重症监护病房（ICU）管理的改进以及更精细的分诊标准。这些发现导致了对NIV在此背景下作用的重新评估，表明患有ARF的免疫功能受损患者可能受益于与普通人群相似的治疗策略，包括在临床指征时及时插管。值得注意的是，生存结果仍然受到研究中不一致的插管标准、免疫抑制的根本原因以及患者严重程度的影响。最近的研究还强调了具有特定血液肿瘤特征和脆弱身体状况的患者ICU预后较差，这降低了在这些亚组中进行有创支持的热情。识别NIV失败的预测因素对于指导免疫功能受损ARF患者的通气策略以及确定何时持续的非侵入性支持可能适得其反至关重要。然而，由于没有经过验证的工具来预测这些患者NIV的成功或失败，仔细评估他们对非侵入性策略的反应对于确保及时插管并防止在那些没有改善迹象的患者中出现危险的延误至关重要。在NIV广泛应用之后，高流量鼻导管氧疗的引入已成为管理特定呼吸衰竭场景的新工具，在影响危重患者预后方面发挥着核心作用。其在免疫功能受损患者中的有效性也已得到研究。

### 第二部分 AI 大师评价

本研究系统回顾了无创通气在免疫功能受损患者呼吸衰竭中的应用现状与演变。研究通过文献综述方法，揭示了随着肿瘤治疗和ICU管理的进步，免疫功能受损患者插管死亡率显著下降，从而需要重新评估NIV的临床定位。关键发现包括NIV失败预测因素的重要性，以及高流量鼻导管氧疗作为新兴治疗工具的价值。该研究的创新性在于动态评估了NIV在免疫功能受损人群中的角色转变，具有重要的临床指导意义，但局限性在于缺乏验证的NIV预后预测工具，需要依赖临床床旁评估来指导治疗决策。

---

## 18. 选择性细胞分离装置联合连续性肾脏替代疗法在儿童中的应用：当代队列比较研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41129413](https://pubmed.ncbi.nlm.nih.gov/41129413)
**期刊：** Blood purification
**PMID：** 41129413
**DOI：** 10.1159/000549111

### 第一部分 原文与翻译

**英文原标题：** Use of the Selective Cytopheretic Device with Continuous Renal Replacement Therapy in Children: A Comparison of Contemporary Cohorts.

**英文摘要原文：**
INTRODUCTION: The Selective Cytopheretic Device (SCD) is a cell-directed extracorporeal therapy approved for use in children with acute kidney injury (AKI) receiving continuous renal replacement therapy (CRRT) with sepsis/sepsis-like conditions. We compared outcomes for children treated with SCD to a contemporary cohort of children treated with CRRT alone.

METHODS: Secondary analysis and comparison of patients ≤22 years old and ≥10 kg from a multicenter registry of patients receiving CRRT for AKI and/or fluid overload (WE-ROCK; 2015-2021) to patients from two multicenter, prospective, interventional studies of children with AKI and multiple organ dysfunction (MODS) receiving SCD (SCD-PED-01/SCD-PED-02; 2016-2022).

RESULTS: Eighteen patients in the SCD Cohort were compared to 178 in the CRRT Cohort. There were no differences between cohorts at CRRT+/-SCD initiation. SCD patients had shorter CRRT duration (6 [3,11] vs. 10 [5,18] days, p=0.013) and shorter ICU length of stay (LOS) in survivors (16 [11,25] vs. 27 [16,46] days, p=0.012). Survival to ICU discharge or Day 60 was 94% in the SCD Cohort vs. 74% in the CRRT Cohort (p=0.079). A Bayesian analysis demonstrated a >99% probability of improved survival with SCD. A sub-analysis in septic patients demonstrated greater survival (100% vs. 69%, p=0.032), shorter CRRT duration (5 [3,7] vs. 11 [6,17] days, p=0.006) and reduced ICU LOS in survivors (21 [10,25] vs. 27 [16,45] days, p=0.027) in SCD-treated patients.

CONCLUSIONS: The addition of SCD therapy in children with AKI and MODS receiving CRRT may be beneficial, though larger prospective studies are needed.

**中文摘要译文：**
引言：选择性细胞分离装置（SCD）是一种细胞导向的体外治疗方法，已被批准用于接受连续性肾脏替代疗法（CRRT）且伴有脓毒症/脓毒症样状况的急性肾损伤（AKI）儿童患者。我们将接受SCD治疗的儿童结局与仅接受CRRT治疗的当代队列儿童进行了比较。

方法：对来自多中心注册研究中因AKI和/或液体过负荷接受CRRT治疗的患者（WE-ROCK；2015-2021年）中年龄≤22岁且体重≥10公斤的患者，与来自两项多中心、前瞻性、干预性研究（SCD-PED-01/SCD-PED-02；2016-2022年）中患有AKI和多器官功能障碍（MODS）并接受SCD治疗的儿童患者进行二次分析和比较。

结果：SCD队列中的18名患者与CRRT队列中的178名患者进行了比较。在CRRT±SCD开始时，两组队列之间没有差异。SCD患者的CRRT持续时间更短（6 [3,11] 天 vs. 10 [5,18] 天，p=0.013），且存活者的ICU住院时间更短（16 [11,25] 天 vs. 27 [16,46] 天，p=0.012）。SCD队列中存活至ICU出院或第60天的比例为94%，而CRRT队列为74%（p=0.079）。贝叶斯分析显示，使用SCD改善生存率的概率>99%。对脓毒症患者的亚组分析显示，接受SCD治疗的患者具有更高的生存率（100% vs. 69%，p=0.032）、更短的CRRT持续时间（5 [3,7] 天 vs. 11 [6,17] 天，p=0.006）以及存活者中更短的ICU住院时间（21 [10,25] 天 vs. 27 [16,45] 天，p=0.027）。

结论：在接受CRRT治疗的AKI和MODS儿童中加用SCD治疗可能有益，但仍需更大规模的前瞻性研究。

### 第二部分 AI 大师评价

本研究通过比较选择性细胞分离装置联合CRRT与单纯CRRT在儿童急性肾损伤伴多器官功能障碍中的疗效，发现SCD治疗组在CRRT持续时间、ICU住院时间和生存率方面均显示出显著优势。该研究创新性地应用了细胞导向的体外治疗技术，为重症儿童提供了新的治疗策略。研究结果具有重要的临床价值，特别是对脓毒症患儿的治疗效果尤为突出，贝叶斯分析进一步支持了其生存获益。然而，研究样本量有限且为回顾性分析，未来需要更大规模的前瞻性随机对照试验来验证这些发现。

---

## 19. 雾化支气管扩张剂增强痰液诱导在泰国疑似肺结核患者中的有效性：一项随机对照试验（NeB-TB试验）

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41125243](https://pubmed.ncbi.nlm.nih.gov/41125243)
**期刊：** Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
**PMID：** 41125243
**DOI：** 10.1093/cid/ciaf580

### 第一部分 原文与翻译

**英文原标题：** Effectiveness of Nebulized Bronchodilator - Enhanced Sputum Induction in Thai Patients with Presumed Pulmonary Tuberculosis; A Randomized Controlled Trial; (NeB-TB Trial).

**英文摘要原文：**
BACKGROUND: Delayed pulmonary tuberculosis (TB) diagnosis, especially with limited bronchoscopy resources, worsens outcomes and increases transmission risks. Sputum induction offers a non-invasive and effective alternative. We investigated whether adding nebulized bronchodilators improves sputum induction effectiveness for presumed pulmonary TB.

METHODS: In a randomized controlled trial at King Chulalongkorn Memorial Hospital, Thailand, 204 adults with presumed pulmonary TB and negative Xpert MTB/RIF Ultra results or inadequate sputum production were enrolled between July and October 2024. Participants were randomly assigned to conventional sputum induction (3% hypertonic saline alone; n=101) or bronchodilator-enhanced induction (nebulized bronchodilator plus 3% hypertonic saline; n=103). The primary outcome was TB diagnosis by Xpert MTB/RIF assay.

RESULTS: TB detection rates by Xpert MTB/RIF were significantly higher in the bronchodilator-enhanced group (30.1%; number needed to diagnose [NND]=4) versus the conventional group (17.8%; NND=6), with a 12.3% difference (RR, 1.68; 95%CI, 1.01-2.80). The group receiving bronchodilator co-administration showed a trend towards higher mycobacterial culture positivity (RR 1.49; 95%CI 0.93-2.41) and a lower need for bronchoscopy (RR 0.41; 95%CI 0.15-1.12). They also experienced fewer adverse events and required fewer induction attempts, significantly assisting us to be able to provide early treatment to the patients (median 4.5 vs. 14 days; p<0.01). Subgroup analysis revealed a significant benefit among outpatients (RR 1.86; 95%CI 1.00-3.48).

CONCLUSION: Bronchodilator-enhanced sputum induction demonstrated superiority over conventional induction, with higher diagnostic yield, fewer adverse events, fewer invasive procedures, and significantly earlier TB treatment initiation, supporting its potential as a new standard for TB diagnosis.

CLINICAL TRIALS REGISTRATION: Thai Clinical Trials Registry (TCTR20240709001), registered on July 9, 2024.

**中文摘要译文：**
背景：肺结核诊断延迟，特别是在支气管镜检查资源有限的情况下，会恶化患者预后并增加传播风险。痰液诱导提供了一种无创且有效的替代方法。我们研究了添加雾化支气管扩张剂是否能提高痰液诱导在疑似肺结核患者中的有效性。

方法：在泰国朱拉隆功国王纪念医院进行的一项随机对照试验中，于2024年7月至10月期间纳入了204名疑似肺结核且Xpert MTB/RIF Ultra检测结果为阴性或痰液产生不足的成人患者。参与者被随机分配至常规痰液诱导组（仅使用3%高渗盐水；n=101）或支气管扩张剂增强诱导组（雾化支气管扩张剂加3%高渗盐水；n=103）。主要结局是通过Xpert MTB/RIF检测诊断肺结核。

结果：支气管扩张剂增强组的Xpert MTB/RIF结核检测率显著高于常规组（30.1%；需诊断人数[NND]=4 vs 17.8%；NND=6），差异为12.3%（RR，1.68；95%CI，1.01-2.80）。接受支气管扩张剂联合给药的组别显示出较高的分枝杆菌培养阳性率趋势（RR 1.49；95%CI 0.93-2.41）和较低的支气管镜检查需求（RR 0.41；95%CI 0.15-1.12）。他们还经历了较少的不良事件，需要较少的诱导尝试，显著帮助我们能够为患者提供早期治疗（中位数4.5天 vs 14天；p<0.01）。亚组分析显示门诊患者获益显著（RR 1.86；95%CI 1.00-3.48）。

结论：支气管扩张剂增强痰液诱导显示出优于常规诱导的优势，具有更高的诊断率、更少的不良事件、更少的侵入性操作以及显著更早的结核治疗开始时间，支持其作为结核诊断新标准的潜力。

临床试验注册：泰国临床试验注册中心（TCTR20240709001），于2024年7月9日注册。

### 第二部分 AI 大师评价

本研究通过随机对照试验评估了雾化支气管扩张剂增强痰液诱导在疑似肺结核诊断中的有效性。研究创新性地将支气管扩张剂与高渗盐水联合使用，显著提高了结核分枝杆菌的检出率（30.1% vs 17.8%），并减少了不良事件和侵入性操作需求。该方法不仅缩短了诊断至治疗的时间（4.5天 vs 14天），还特别适用于门诊患者，在资源有限地区具有重要临床价值。虽然研究显示了良好的应用前景，但样本量相对有限，且部分次要结局指标未达到统计学显著性，未来需要更大规模的多中心研究进一步验证其推广价值。

---

## 20. 靶向二价阳离子的化学定制阴离子抗生素佐剂用于克服革兰氏阴性菌对碳青霉烯类药物的耐药性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41124267](https://pubmed.ncbi.nlm.nih.gov/41124267)
**期刊：** Science advances
**PMID：** 41124267
**DOI：** 10.1126/sciadv.adz0574

### 第一部分 原文与翻译

**英文原标题：** Chemically tailored anionic antibiotic adjuvants targeting divalent cations to overcome carbapenem resistance in gram-negative bacteria.

**英文摘要原文：**
No clinically available antibiotic adjuvants can overcome metallo-β-lactamase (MBL) resistance in carbapenem-resistant Gram-negative ESKAPE pathogens. Divalent cations in MBL and quasicrystalline lipopolysaccharides (LPS) are key determinants of acquired and intrinsic resistance in these bacteria. Chemically depriving these cations would block multiple resistance pathways simultaneously and restore carbapenem susceptibility. Here, we chemically engineer a class of anionic adjuvants to tailor their interactions with MBL, enhancing the enzymatic inhibition by up to ~5885-fold compared to parent compounds. An orthogonal screen identifies the tiopronin-engineered anionic adjuvant (TINA), which achieves complete rescue of all tested carbapenems against diverse New Delhi metallo-β-lactamase-1-producing Gram-negative ESKAPE bacteria. TINA targets both MBL and LPS, depriving divalent cations to inactivate MBL and damage membrane collaboratively while also preventing resistance evolution. Moreover, TINA's anionic nature minimizes serum adsorption, enabling safe and effective in vivo treatment of bacterial pneumonia. This work provides an innovative chemical生物学 strategy leveraging anionic materials to combat superbugs globally.

**中文摘要译文：**
目前临床上尚无可用的抗生素佐剂能够克服耐碳青霉烯类革兰氏阴性ESKAPE病原体中金属β-内酰胺酶（MBL）的耐药性。MBL和准晶状脂多糖（LPS）中的二价阳离子是这些细菌获得性和固有耐药性的关键决定因素。化学性剥夺这些阳离子将同时阻断多个耐药途径并恢复对碳青霉烯类药物的敏感性。在此，我们通过化学工程方法设计了一类阴离子佐剂，以定制其与MBL的相互作用，与母体化合物相比，酶抑制作用提高了约5885倍。通过正交筛选鉴定出硫普罗宁工程化阴离子佐剂（TINA），该佐剂能够完全挽救所有测试的碳青霉烯类药物，对抗多种产新德里金属β-内酰胺酶-1的革兰氏阴性ESKAPE细菌。TINA同时靶向MBL和LPS，通过剥夺二价阳离子协同灭活MBL并破坏细胞膜，同时还能防止耐药性进化。此外，TINA的阴离子特性最大限度地减少了血清吸附，使得能够安全有效地在体内治疗细菌性肺炎。这项工作提供了一种创新的化学生物学策略，利用阴离子材料来全球性地对抗超级细菌。

### 第二部分 AI 大师评价

本研究旨在开发新型抗生素佐剂以应对革兰氏阴性菌对碳青霉烯类药物的耐药性危机。研究团队采用化学工程方法设计阴离子佐剂，通过靶向金属β-内酰胺酶和脂多糖中的二价阳离子，实现了多重耐药途径的协同阻断。关键发现是硫普罗宁工程化阴离子佐剂（TINA）能够将酶抑制作用提高近6000倍，并完全恢复碳青霉烯类药物对多重耐药菌的活性。这项研究的创新性在于首次利用阴离子材料的独特性质同时靶向获得性和固有耐药机制，其临床价值体现在TINA具有良好的体内安全性和有效性，为全球抗超级细菌提供了全新的化学生物学策略。虽然研究显示了良好的应用前景，但未来仍需进一步验证其在更广泛临床环境中的长期安全性和有效性。

---

## 21. 用于急性肾损伤早期诊断和预后评估的可激活荧光比率探针

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41124265](https://pubmed.ncbi.nlm.nih.gov/41124265)
**期刊：** Science advances
**PMID：** 41124265
**DOI：** 10.1126/sciadv.aea1654

### 第一部分 原文与翻译

**英文原标题：** Activatable fluorescent ratiometric probes for early diagnosis and prognostic assessment of acute kidney injury.

**英文摘要原文：**
Early and accurate diagnosis of acute kidney injury (AKI) is crucial for clinical treatment. However, most existing fluorescent probes are prone to background interference and limited renal targeting. We developed a ratiometric nanoprobe (RP-SC) that synergistically responded to HO and targeted kidney injury molecule-1 (KIM-1). In AKI kidneys, RP-SC was hydrolyzed and slowly released encapsulated Hcy-BOH and Cy-Dopa. The HO level was semi-quantitatively analyzed by fluorescence ratio (/). RP-SC exhibited prominent renal fluorescence in AKI mice, making it possible to accurately diagnose AKI and dynamically monitor renal function for up to 60 hours. RP-SC could monitor the process of AKI in vivo and provide an earlier warning of AKI than traditional strategies, subsequently evaluating the recovery of renal function after -acetyl cysteine (NAC) treatment. Our study confirmed the ability of RP-SC for longitudinal monitoring of renal function in vivo by dual-targeting capacity, providing an effective tool for accurate diagnosis of early AKI while tracking the dynamic process of AKI treatment.

**中文摘要译文：**
急性肾损伤（AKI）的早期准确诊断对于临床治疗至关重要。然而，大多数现有的荧光探针容易受到背景干扰且肾脏靶向性有限。我们开发了一种比率纳米探针（RP-SC），能够协同响应HO并靶向肾脏损伤分子-1（KIM-1）。在AKI肾脏中，RP-SC被水解并缓慢释放封装的Hcy-BOH和Cy-Dopa。通过荧光比率（/）对HO水平进行半定量分析。RP-SC在AKI小鼠中表现出显著的肾脏荧光，使其能够准确诊断AKI并动态监测肾功能长达60小时。RP-SC能够在体内监测AKI的过程，并提供比传统策略更早的AKI预警，随后评估N-乙酰半胱氨酸（NAC）治疗后肾功能的恢复情况。我们的研究证实了RP-SC通过双靶向能力在体内纵向监测肾功能的能力，为早期AKI的准确诊断提供了有效工具，同时跟踪AKI治疗的动态过程。

### 第二部分 AI 大师评价

本研究开发了一种创新的比率纳米探针RP-SC，通过协同响应HO和靶向KIM-1的双重机制，实现了急性肾损伤的早期诊断和动态监测。该探针具有显著的技术优势：能够半定量分析HO水平、提供长达60小时的肾功能监测窗口、比传统方法更早预警AKI发生。其创新性在于双靶向设计克服了现有探针的背景干扰和靶向性不足问题，为AKI的精准诊疗提供了重要工具。该技术不仅有助于早期诊断，还能动态评估治疗效果，具有重要的临床转化价值。不过，该研究主要基于小鼠模型，其临床应用效果仍需进一步验证。

---

## 22. 免疫功能受损患者肺炎的通用诊疗策略：基于最新共识文件的见解

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40997866](https://pubmed.ncbi.nlm.nih.gov/40997866)
**期刊：** Seminars in respiratory and critical care medicine
**PMID：** 40997866
**DOI：** 10.1055/a-2709-6182

### 第一部分 原文与翻译

**英文原标题：** General Approach to Immunocompromised Patients with Pneumonia: Insights from the Latest Consensus Documents.

**英文摘要原文：**
Immunocompromised adults with pneumonia represent a growing and heterogeneous patient population requiring a tailored diagnostic and therapeutic approach. This review synthesizes insights from the latest consensus documents and guidelines to provide a structured framework for clinicians managing pneumonia in immunocompromised hosts. Patients are stratified into four categories of immune dysfunction: Severely immunocompromised, immunocompromised, abnormal immune system (not at risk for opportunistic pathogens), and no identifiable immune abnormality. This classification informs both the likelihood of infection with core respiratory pathogens and opportunistic pathogens. A comprehensive microbiological evaluation is critical, incorporating sputum, nasopharyngeal swabs, blood cultures, urinary antigens, and, when indicated, bronchoalveolar lavage and biopsy. For most immunocompromised patients presenting with community-acquired pneumonia, empiric therapy parallels that of non-immunocompromised hosts. Empiric coverage for opportunistic pathogens is warranted in unstable patients with compatible risk factors, when delayed therapy may increase mortality.

**中文摘要译文：**
免疫功能受损成人肺炎患者是一个日益增长且异质性的患者群体，需要个体化的诊断和治疗策略。本综述综合了最新共识文件和指南的见解，为临床医生管理免疫功能受损宿主肺炎提供了一个结构化的框架。患者根据免疫功能障碍程度分为四个类别：严重免疫功能受损、免疫功能受损、免疫系统异常（不处于机会性病原体感染风险）以及无明确免疫异常。这种分类有助于评估核心呼吸道病原体和机会性病原体感染的可能性。全面的微生物学评估至关重要，包括痰液、鼻咽拭子、血培养、尿液抗原检测，以及必要时进行支气管肺泡灌洗和活检。对于大多数表现为社区获得性肺炎的免疫功能受损患者，经验性治疗与非免疫功能受损宿主相似。对于病情不稳定且具有相应危险因素的患者，当延迟治疗可能增加死亡率时，需要经验性覆盖机会性病原体。

### 第二部分 AI 大师评价

本研究系统综述了免疫功能受损患者肺炎的最新诊疗共识，具有重要的临床指导价值。研究采用文献综述方法，整合最新指南和共识文件，构建了免疫功能受损患者的四层分类体系，为个体化诊疗提供了理论框架。关键创新在于建立了基于免疫状态的风险分层模型，明确了不同免疫缺陷程度患者的核心病原体和机会性病原体感染风险。该研究为临床医生提供了实用的诊断流程和治疗策略，特别强调了全面微生物学评估的重要性。主要局限性在于作为综述性研究，缺乏原始临床数据支持，且可能无法完全覆盖所有特殊免疫缺陷类型的患者群体。

---

## 23. 肿瘤患者药物性肺炎的评估

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40967605](https://pubmed.ncbi.nlm.nih.gov/40967605)
**期刊：** Seminars in respiratory and critical care medicine
**PMID：** 40967605
**DOI：** 10.1055/a-2703-4574

### 第一部分 原文与翻译

**英文原标题：** The Evaluation of the Oncologic Patient for Drug-Induced Pneumonitis.

**英文摘要原文：**
The National Cancer Institute (NCI) estimates that over 2 million Americans will be diagnosed with cancer in 2025. A significant proportion of these patients will receive chemotherapeutics, radiation, molecularly targeted therapies, or immunotherapies-many of which are associated with pulmonary toxicity. Drug-induced interstitial lung disease (D-ILD) is a growing and well-recognized complication of cancer-related therapies, carrying substantial morbidity and mortality. In addition to its direct health impact, D-ILD often necessitates modification or discontinuation of cancer treatment, further complicating oncologic care. As such, pulmonologists must be proficient in the evaluation and management of suspected D-ILD. In this review, we propose a structured approach to assessing patients with malignancy who present with diffuse parenchymal lung disease. We also summarize commonly implicated cancer therapies and their associated pulmonary toxicities.

**中文摘要译文：**
美国国家癌症研究所(NCI)估计，2025年将有超过200万美国人被诊断出癌症。这些患者中有相当大一部分将接受化疗、放疗、分子靶向治疗或免疫治疗，其中许多治疗方法都与肺毒性相关。药物性间质性肺病(D-ILD)是癌症相关治疗中日益增多且公认的并发症，具有显著的发病率和死亡率。除了对健康的直接影响外，D-ILD通常需要修改或停止癌症治疗，进一步使肿瘤治疗复杂化。因此，呼吸科医生必须熟练掌握疑似D-ILD的评估和管理。在本综述中，我们提出了一种结构化方法来评估出现弥漫性肺实质病变的恶性肿瘤患者。我们还总结了常见的相关癌症治疗方法及其相关的肺毒性。

### 第二部分 AI 大师评价

本研究旨在为肿瘤患者药物性肺炎的评估提供系统化方法，具有重要的临床应用价值。文章采用综述形式，系统梳理了癌症治疗相关肺毒性的现状，并提出了结构化的评估框架。其创新性在于将复杂的药物性肺损伤评估标准化，为临床医生提供了实用的诊断思路。该研究对于改善肿瘤患者治疗安全性和生活质量具有重要指导意义，但作为综述性文章，缺乏原始研究数据的支持是其局限性所在。

---

## 24. 隐源性机化性肺炎

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40967604](https://pubmed.ncbi.nlm.nih.gov/40967604)
**期刊：** Seminars in respiratory and critical care medicine
**PMID：** 40967604
**DOI：** 10.1055/a-2703-4537

### 第一部分 原文与翻译

**英文原标题：** Cryptogenic Organizing Pneumonia.

**英文摘要原文：**
Cryptogenic organizing pneumonia (COP), formerly called bronchiolitis obliterans organizing pneumonia (BOOP), was first described in the 1980s and is classified as a rare idiopathic interstitial pneumonia (IIP). COP classically presents in a subacute fashion following a flu-like illness with fever, non-productive cough, and fatigue. Imaging often reveals diffuse, bilateral, peribronchovascular and peripheral, consolidative and ground-glass opacities although various imaging subtypes also exist. Physical examination may be normal or reveal inspiratory crackles. Hypoxemia, when present, is commonly identified with exertion but can also occur at rest. Diagnostic evaluation relies on excluding secondary causes of organizing pneumonia and includes a thorough history including medications, exposures, and signs or symptoms of underlying rheumatologic disease. Invasive diagnostic testing including tissue sampling allows for histopathologic confirmation of COP while excluding secondary causes including infection and malignancy. Although video-assisted thoracoscopic surgery (VATS) lung biopsy is often the preferred method of obtaining sufficient tissue, less invasive means may be employed based on patient-specific factors. A defining feature of COP is steroid-responsiveness, and most experts recommend prolonged corticosteroid courses (6-12 months). Response to corticosteroids and prognosis are typically excellent. Relapse rates range from 25 to 50% and occur most often during steroid taper or complete withdrawal necessitating additional therapy. Steroid-sparing immunosuppression may be used in select circumstances. Further study is needed to define optimal corticosteroid dose and duration.

**中文摘要译文：**
隐源性机化性肺炎（COP），既往称为闭塞性细支气管炎伴机化性肺炎（BOOP），最早于20世纪80年代被描述，被归类为一种罕见的特发性间质性肺炎（IIP）。COP典型表现为流感样疾病后的亚急性起病，伴有发热、干咳和乏力。影像学检查常显示弥漫性、双侧性、支气管血管周围及外周分布的实变和磨玻璃影，尽管也存在多种影像学亚型。体格检查可能正常或可闻及吸气性爆裂音。低氧血症（若存在）通常在活动时被发现，但也可在静息时发生。诊断评估依赖于排除机化性肺炎的继发性原因，并包括详细的病史采集，涵盖用药史、暴露史以及潜在风湿性疾病的体征或症状。包括组织取样在内的有创诊断性检查可在排除感染和恶性肿瘤等继发性原因的同时，对COP进行组织病理学确认。虽然电视辅助胸腔镜手术（VATS）肺活检通常是获取足够组织的首选方法，但根据患者具体情况也可能采用创伤性较小的方法。COP的一个定义性特征是对类固醇治疗有反应，大多数专家推荐长疗程糖皮质激素治疗（6-12个月）。对糖皮质激素的反应和预后通常良好。复发率在25%至50%之间，最常发生在类固醇减量或完全停药期间，需要额外治疗。在特定情况下可使用类固醇节约型免疫抑制剂。需要进一步研究以确定最佳的糖皮质激素剂量和疗程。

### 第二部分 AI 大师评价

本研究系统综述了隐源性机化性肺炎（COP）的临床特征、诊断方法和治疗策略，为这一罕见特发性间质性肺炎提供了全面的临床管理指南。研究采用文献回顾和临床经验总结的方法，详细阐述了COP的临床表现、影像学特征、诊断流程及治疗原则。关键发现包括COP对糖皮质激素治疗的良好反应性、25-50%的复发率特点，以及电视辅助胸腔镜手术在诊断中的重要作用。该研究的创新性在于整合了最新的临床证据，为这一罕见疾病的规范化诊疗提供了重要参考，具有显著的临床实用价值。然而，研究也指出需要进一步明确最佳糖皮质激素剂量和疗程，这反映了当前治疗标准化的局限性。

---

速递结束，祝您工作愉快！